SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Corixa [CRXA] - cancer vaccines
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Andreas Helke who started this subject10/29/2001 4:41:32 AM
From: nigel bates  Read Replies (1) of 222
 
LONDON, Oct 29 (Reuters) - British healthcare group Amersham Plc said on Monday it had agreed to market Bexxar, a treatment for non-Hodgkin's lymphoma being developed by Corixa Corp (NasdaqNM:CRXA - news), in Europe.
Non-Hodgkin's lymphoma is a form of cancer that affects the blood and lymph tissues. More than 40,000 patients are diagnosed with the disease in Europe's five largest countries each year.
Under terms of the deal, Corixa will generate clinical trial data for Bexxar's registration in Europe and Amersham will manufacture and sell it across the continent, though under a different name.
Amersham will also buy $15 million in Corixa common stock at a premium, which it did not disclose, and the rest of the company's shares in the future as decided by Corixa.
In addition, it will pay Corixa multi-million dollar milestone payments when European regulators approve Bexxar and the drug achieves undisclosed sales volumes.
Amersham will also pay Corixa undisclosed royalties on all future sales of its products in Europe.
Bexxar, a radioimmunotherapy treatment that combines monoclonal antibody and radiation therapy, is currently under review by the U.S. Food and Drug Administration...
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News